Given that ID1 promotes AKT1 phosphorylation through its C-terminal region without disrupting its interaction with bHLH, combined targeting of ID1 and AKT1 might be a promising therapeutic strategy for leukemia [76]. This evidence concerns the gene AKT1 and leukemia.